Antitrust Has a Generic-Drug Problem
Brand-name drugmakers like to pay lower-cost rivals not to compete—and courts too often let them.

Brand-name drugmakers like to pay lower-cost rivals not to compete—and courts too often let them.

A simple law would stop the U.S. government from rubber-stamping corporate consolidation.

Tougher regulation will help, but workers and small businesses also need the ability to join forces against corporate power.
